-
Media Release
TV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis
-
Media Release
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media Release
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
-
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
-
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
-
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
-
Media Release
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims